stoxline Quote Chart Rank Option Currency Glossary
  
TransCode Therapeutics, Inc. (RNAZ)
1.08  -0.05 (-4.41%)    06-18 10:56
Open: 1.13
High: 1.14
Volume: 108,606
  
Pre. Close: 1.13
Low: 1.06
Market Cap: 7(M)
Technical analysis
2024-06-18 10:52:13 AM
Short term     
Mid term     
Targets 6-month :  1.62 1-year :  2.32
Resists First :  1.39 Second :  1.99
Pivot price 1.32
Supports First :  0.42 Second :  0.35
MAs MA(5) :  1.16 MA(20) :  1.38
MA(100) :  0.83 MA(250) :  23.56
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  17.7 D(3) :  20.5
RSI RSI(14): 46.4
52-week High :  128 Low :  0.41
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ RNAZ ] has closed above bottom band by 20.8%. Bollinger Bands are 10.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.21 - 1.21 1.21 - 1.22
Low: 1.11 - 1.12 1.12 - 1.13
Close: 1.12 - 1.13 1.13 - 1.14
Company Description

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Headline News

Mon, 10 Jun 2024
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements - StockTitan

Mon, 10 Jun 2024
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing ... - WDRB

Mon, 03 Jun 2024
RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q1 2024 - InvestorPlace

Mon, 13 May 2024
TransCode Therapeutics Open Letter to Shareholders | $RNAZ Stock News - StockTitan

Mon, 13 May 2024
Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered - TransCode Therapeutics (NASDAQ:RNAZ) - Benzinga

Mon, 13 May 2024
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 7 (M)
Held by Insiders 6.25e+006 (%)
Held by Institutions 0.1 (%)
Shares Short 19 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -173 %
Return on Equity (ttm) -784.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -19.6
Qtrly Earnings Growth 885.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -0.37
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 173930
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android